AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2024
Dec 15, 2024
33869_rns_2024-12-15_886c5c74-dbe4-4ced-b303-2cab6d520985.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Market Announcement
==> picture [33 x 50] intentionally omitted <==
16 December 2024
==> picture [451 x 5] intentionally omitted <==
Anteris Technologies Global Corp. (formerly Anteris Technologies Ltd) (ASX: AVR) – Admission and Quotation
Description
Anteris Technologies Limited (‘ATL’) was admitted to the Official List of ASX on 24 March 2004.
On 13 August 2024 ATL announced that it had entered into a scheme implementation deed with Anteris Technologies Global Corp. (‘ATGC’) to pursue a re-domiciliation of ATL and its subsidiaries (‘Anteris Group’) from Australia to the United States of America by way of proposed schemes of arrangement with its shareholders under Part 5.1 of the Corporations Act 2001 (Cth) (‘Share Scheme’) and its optionholders (‘Option Scheme’) (together, the ‘Schemes’). ATGC will acquire 100% of ATL’s issued shares, ATL optionholders will exchange their options in ATL for equivalent securities in ATGC, and ATGC will become the new ultimate parent company of the Anteris Group effectively redomiciling ATL to the United States of America.
On 4 December 2024 ATL announced that the Supreme Court of Queensland granted orders approving the Schemes.
On 5 December 2024 ATL announced that the Schemes were now legally effective and ATL’s shares were suspended from trading on ASX from the close of trade.
On 13 December 2024 ATL announced that the conditions of the Schemes have been satisfied.
ATGC will be admitted to the official list of ASX today, 16 December 2024.
It is anticipated that the ATGC CDIs representing ATGC shares at a ratio of 1:1 (i.e. 1 CDI confers a beneficial interest in one fully paid ordinary ATGC share) will commence quotation at approximately 10:00am (AEDT) on 17 December 2024.
No funds were raised by ATGC in connection with its listing on ASX.
ATGC expects to raise US$88.8 million under its initial public offering (‘IPO’) and listing on NASDAQ, which is scheduled to close on 16 December 2024 (US time). ATGC will release an ASX announcement confirming the closing of the IPO prior to the commencement of trading on ASX on 17 December 2024. ATGC’s shares commenced trading on NASDAQ on 13 December 2024.
Quotation information
| Quoted securities | Fully paid ordinary shares: 20,360,496 common stock (to be settled in the |
|---|---|
| form of 20,360,496 CDIs) | |
| CDI ratio | Fully paid ordinary shares: CDI 1:1 |
| ASX code | CDI: AVR |
| Time | 10:00:00 AM +/- 15 secs AEDT |
| Date | Tuesday, 17 December 2024 |
| ASX trade abbreviation | ANTERIS |
| ISIN | CDI: AU0000088841 |
Market Announcement 1/3 ASX Customer Service Centre 131 279 | asx.com.au
16 December 2024 ASX Limited
10840494v1
==> picture [33 x 50] intentionally omitted <==
| Registered office | Anteris Technologies Global Corp. |
|---|---|
| Address: 251 Little Falls Drive, in the city of Wilmington, County of New | |
| Castle 19808 Delaware, USA | |
| Phone: (302) 636 5401 | |
| Email: [email protected] | |
| Company secretary | Wayne Geoffrey Paterson |
| Share registry | Computershare Investor Services Pty Limited |
| Address: Computershare Investor Services Pty Limited – Level 1, 200 Mary | |
| Street, Brisbane QLD 4000. | |
| Phone: 1300 850 505 (within Australia) or +61 3 9415 5000 (outside | |
| Australia) | |
| Email: www-au.computershare.com/Investor/#Contact/Enquiry | |
| Computershare Trust Company, N.A. – registry in the United States in | |
| connection with Anteris Technologies Global Corp.’s shares of common | |
| stock. | |
| Address: 150 Royall Street, Canton, MA 02021. | |
| Phone: +61 3 9473 2555 | |
| Email:web.queries@computershare | |
| Balance date | 31 December |
| CHESS | Participating. CHESS and Issuer Sponsored. |
| Place of incorporation | Delaware, United States of America |
| Dividend policy | See section 6.4 of the Scheme Booklet. |
| Activities | Anteris Technologies Global Corp will act as the ultimate holding company |
| of Anteris Technologies Ltd and its subsidiaries who focus on developing | |
| next-generation technologies that help healthcare professionals deliver | |
| consistent life-changing outcomes for patients. | |
| Lead manager | n/a |
| Underwriter | n/a |
| ASX restricted securities | n/a |
| Other securities not quoted | 6,117,807 options with various exercise prices and expiry dates. |
| 15,579,320 shares. | |
| 4,956,750 Convertible Notes. | |
| 749,999 Restricted Stock Units. |
What do I need to do and by when?
For further details, please refer to ATL’s announcements, the Scheme Booklet and Supplementary Scheme Booklet.
Market Announcement 2/3
16 December 2024
10840494v1
==> picture [33 x 50] intentionally omitted <==
Need more information?
For further information, please call the ATL Schemes Information Line on 1300 264 812 (within Australia) or +61 3 9415 4634 (outside Australia) Monday to Friday between 7:30 am (AEST) and 4:00 pm (AEST) / 8:30 am (AEDT) and 5:00 pm (AEDT).
Disclaimer
Please refer to the following disclaimer.
Issued by
ASX Compliance
Market Announcement 3/3
16 December 2024